GlassScriptPhysician profile
John H Upshaw
NPI 1598770869
$2,848.27
in general payments reported to CMS, 2019-2025
32 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $316 · 2021: $459 · 2022: $438 · 2023: $113 · 2024: $265 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.45 |
| Education | $164.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $526.64 | 2019-2025 | Xtandi, Myrbetriq |
| Coloplast Corp | $278.45 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $217.38 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $200.98 | 2022-2025 | Erleada |
| Boston Scientific Corporation | $141.92 | 2021-2025 | Lumenis Pulse 120h, Rezum Generator |
| Allergan, INC. | $138.07 | 2020-2022 | |
| Abbvie INC. | $126.34 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $123.41 | 2019-2021 | |
| Procept Biorobotics Corporation | $103.50 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Urovant Sciences INC | $99.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $95.70 | 2022-2025 | Imfinzi, Lynparza |
| Urogen Pharma, INC. | $94.31 | 2022-2025 | |
| Travere Therapeutics, INC. | $78.49 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $74.27 | 2022 | |
| Ferring Pharmaceuticals INC. | $71.31 | 2019-2025 | Adstiladrin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $63.21 | 2019-2020 | |
| Amgen INC. | $57.18 | 2019-2021 | |
| Pfizer INC. | $49.20 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.50 | 2019-2022 | |
| Tolmar, INC. | $33.81 | 2024 | |
| Zyla Life Sciences, INC. | $29.09 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $26.11 | 2020 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Lynparza |
| Teleflex LLC | $20.16 | 2025 | Barrigel |
| Olympus America INC. | $18.94 | 2024 | Itind System |
| Accord Healthcare, INC. | $18.94 | 2024 | |
| Ambu INC. | $18.87 | 2020 | |
| Myovant Sciences INC. | $17.51 | 2021 | |
| Cook Medical LLC | $17.33 | 2019 | |
| Immunitybio, INC. | $16.39 | 2025 | |
| Antares Pharma, INC. | $15.31 | 2019 | |
| Endo Pharmaceuticals INC. | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Upshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.